StockData

Conmed vs Enovis

CNMD and ENOV side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CNMD and ENOV compare

Conmed and Enovis are about the same size, with market caps of $1.5B and $1.6B.

Enovis grew revenue faster over the last twelve months (4.9% versus 1.6% for Conmed).

Conmed keeps more of each dollar of sales as profit, with a net margin of 5.4% compared with −48.0% at Enovis.

Conmed scores higher on the StockData Score (14 against 8 for Enovis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCNMDENOV
Size and price
Market cap$1.5B$1.6B
Share price$49.35$27.92
Change, 1 year14.1%−9.6%
Change, 5 years−63.5%−80.8%
Beta (5Y)0.350.04
Employees3,9007,802
StockData Score
Total score14 (better)8
Valuation score6 (better)4
Growth score22
Performance score4 (better)0
Health score22
Dividend score00
Valuation
P/E20.4×–
P/S1.1×0.7× (better)
P/B1.4×1.1× (better)
EV/EBITDA16.5×9.3× (better)
P/FCF11.1× (better)25.3×
FCF yield9.0% (better)4.0%
Fair value$67.98$81.36
Margin of safety27.4%65.7% (better)
Growth
Revenue growth (TTM)1.6%4.9% (better)
Revenue growth, 5Y average9.8%14.9% (better)
Net income growth (TTM)14.6%–
EPS growth (TTM)18.0%–
EPS growth, 5Y average36.4%–
Profitability
Gross margin57.6%61.1% (better)
Operating margin9.9% (better)−45.1%
Net margin5.4% (better)−48.0%
FCF margin9.7% (better)2.8%
Return on equity7.1% (better)−54.3%
Return on invested capital5.2% (better)−24.5%
Financial health
Debt / equity0.77 (better)0.87
Net debt / EBITDA5.664.12 (better)
Interest coverage4.1× (better)−30.9×
Current ratio1.491.98 (better)
Altman Z-score2.01 (better)−0.23
Piotroski F-score6 (better)4
Dividends and buybacks
Dividend yield0.00%–
Payout ratio8.4%–
Years of dividend growth0–
Dividend growth, 5Y average−5.6%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions114%122%
Held by insiders0.47%2.7%
Insider net buying, 12 months$0$792K (better)
Superinvestors holding–1
Short interest, % of float6.3%18.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.